A 79-year-old man was admitted to a hospital in Guangzhou, China, with progressive dyspnea and edema. Echocardiography and ...

The benefit of beta-blockers after myocardial infarction in patients with a preserved left ventricular ejection fraction ...

Icotrokinra, a targeted oral peptide that selectively binds the interleukin-23 receptor, is under investigation for the ...

Patients with severe hypertriglyceridemia have an increased risk of acute pancreatitis. The efficacy and safety of olezarsen, ...

Despite guideline recommendations, evidence for the use of non–vitamin K antagonist oral anticoagulant (NOAC) monotherapy in ...

Both tobevibart (a monoclonal antibody) and elebsiran (a small interfering RNA) target hepatitis B virus surface antigen ...

A 26-year-old woman was referred to the pulmonary hypertension clinic with a 6-month history of exertional dyspnea and hoarseness. Vocal-fold paralysis was seen on laryngoscopy (shown in a video).

Personalized therapies hold tremendous promise but challenge traditional models of drug and biologic development. The FDA outlines a path to market entry for products where a randomized trial is no ...

A federal appeals court ruling in United States v. Safehouse may open the door to a new legal defense for harm-reduction interventions in a hostile political climate.

Angiopoietin-like protein 3 (ANGPTL3) inhibits lipoprotein and endothelial lipases. ANGPTL3 loss-of-function genetic variants are associated with decreased levels of low-density lipoprotein ...

We conducted an international, open-label, randomized, blinded-outcome-assessment trial involving 1284 patients who had undergone successful catheter ablation for atrial fibrillation at least 1 year ...

The proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor evolocumab reduces the risk of major adverse cardiovascular events (MACE) among patients with a previous myocardial infarction, ...